Clinical data analysis reveals that high IL30 expression correlates with poor prognosis, whereas high SOCS3 expression is associated with better outcomes, reinforcing the potential clinical relevance of IL30 as a therapeutic target in PC [138]. This evidence concerns the gene IL27 and pachyonychia congenita.